Prognostic value of preoperative albumin-to-fibrinogen ratio (AFR) in patients with bladder cancer treated with radical cystectomy.


Journal

Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460

Informations de publication

Date de publication:
12 2021
Historique:
received: 21 01 2021
revised: 11 04 2021
accepted: 17 04 2021
pubmed: 30 5 2021
medline: 10 2 2022
entrez: 29 5 2021
Statut: ppublish

Résumé

To evaluate the prognostic role of albumin-to-fibrinogen ratio (AFR) for the prediction of oncological outcomes in a multi-institutional cohort of bladder cancer (BC) patients treated with radical cystectomy (RC). We retrospectively analyzed a multicenter cohort of patients treated with upfront RC for localized (cT1-4aN0M0) BC. Multivariable logistic regression analyses were performed to evaluate the ability of AFR to predict non-organ confined (NOC) disease and lymph-node involvement (LNI) at time of RC. Multivariable Cox' regression models were performed to evaluate the prognostic effect of AFR on Time-to-Progression (TTP), overall survival (OS), and cancer-specific survival (CSS). A cut-off value to discriminate between low and high AFR was determined by calculating the receiver operating characteristic (ROC) curve. The area under the curve was 0.73 with an optimal cut-off at 9.53. Data were available for 246 patients (91 with low AFR, 155 with high AFR). Low AFR was associated with characteristics of tumor aggressiveness and independently predicted NOC (OR 2.11, P = 0.02) and LNI (OR 1.58, P = 0.04) at final pathological report. On multivariable Cox' regression analyses, preoperative low AFR was independently associated with worse TTP (HR 2.21, P = 0.02), OS (HR 2.24, P = 0.03), and CSS (HR 2.70, P = 0.01). Preoperative low AFR is a prognostic biomarker for worse TTP, OS, CSS, and is independently associated with adverse tumor pathological features in BC patients undergoing RC. Our results suggest that especially patients with low AFR may be considered for neoadjuvant treatment.

Identifiants

pubmed: 34049782
pii: S1078-1439(21)00184-8
doi: 10.1016/j.urolonc.2021.04.026
pii:
doi:

Substances chimiques

Albumins 0
Fibrinogen 9001-32-5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

835.e9-835.e17

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Francesco Claps (F)

Urological Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy; Department of Urology, Valencian Oncology Institute Foundation, FIVO, Valencia, Spain; Department of Urology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands. Electronic address: claps.francesco@gmail.com.

Samarpit Rai (S)

Department of Urology, University of Louisville, Louisville, KY.

Maria Carmen Mir (MC)

Department of Urology, Valencian Oncology Institute Foundation, FIVO, Valencia, Spain.

Bas W G van Rhijn (BWG)

Department of Urology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.

Giorgio Mazzon (G)

Department of Urology, San Bassiano Hospital, Bassano del Grappa, Italy.

Laura Elizabeth Davis (LE)

Department of Urology, University of Louisville, Louisville, KY.

Crystal Lynn Valadon (CL)

Department of Urology, University of Louisville, Louisville, KY.

Tommaso Silvestri (T)

Department of Urology, San Bassiano Hospital, Bassano del Grappa, Italy.

Michele Rizzo (M)

Urological Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy.

Murali Ankem (M)

Department of Urology, University of Louisville, Louisville, KY.

Giovanni Liguori (G)

Urological Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy.

Antonio Celia (A)

Department of Urology, San Bassiano Hospital, Bassano del Grappa, Italy.

Carlo Trombetta (C)

Urological Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy.

Nicola Pavan (N)

Urological Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH